ArticlePediatric research2026
The impact of ADHD and neurostimulant treatment on normalized height deviance after accounting for genetic height potential.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStudies have reported conflicting findings regarding whether attention-deficit/hyperactivity disorder (ADHD) and neurostimulant (NS) treatment influence growth. The study aimed to evaluate the impact of ADHD and NS-treatment on adult height (AH), while accounting for individual expected height.
methodsRetrospective controlled cohort study using a nationwide healthcare provider database. Children born 1995-2003 were classified into: (1) untreated ADHD, (2) NS-treated ADHD, and (3) controls, followed until AH (girls ≥17 years, boys ≥19 years). Observed height index (OHI) = individual AH ÷ sex-specific mean AH of controls. Expected height index (EHI) = individual's MPH ÷ sex-specific mean MPH of controls. Normalized height deviance (NHD) = OHI - EHI. ADHD impact = mean NHD(untreated ADHD) - mean NHD(controls). NS-treatment impact = mean NHD(NS-treated) - mean NHD(untreated ADHD). Significance was set at p ≤ 0.05. Effect sizes reported as Cohen's d and f.
resultsThe cohort included 17,517 children with ADHD (5671 untreated; 11,846 NS-treated) and 47,258 controls. Girls' ADHD impact was -0.28% (p < 0.001; Cohen's d = 0.08), and in boys -0.11% (p = 0.12; Cohen's d = 0.03). Girls' NS-treatment impact was -0.26% (p = 0.005, Cohen's d = 0.07), in boys -0.10% (p = 0.25).
conclusionsADHD and NS-treatment were associated with negligible effect sizes in girls and non-significant differences in boys. IMPACT: After accounting for individual familial genetic height potential, ADHD and neurostimulant treatment are associated with statistically detectable but clinically negligible differences in adult height. Introduces normalized height deviance (NHD), a genetics-adjusted measure that distinguishes true growth effects from delayed maturation. Uses a large, nationwide cohort followed to adult height, resolving long-standing inconsistencies in prior growth studies. Provides reassurance that ADHD and neurostimulant treatment do not meaningfully impair final adult stature and supports informed clinical decision-making.
Identifiers
42020798What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.